[Skip to Content]
[Skip to Content Landing]
Views 154
Citations 0
Correction
April 2019

Omission in Additional Information

JAMA Oncol. 2019;5(4):580. doi:10.1001/jamaoncol.2019.0708

In the Invited Commentary, “Evaluating Risks and Benefits of Evolving Systemic Treatments of Neuroendocrine Tumors,” published online in the February 14, 2019, issue of JAMA Oncology,1 the following omitted additional information has been added: “Dr Strosberg reports that he was invited to contribute unpublished data to this meta-analysis (reference 3)2 in 2017 but was unable to do so.” This article was corrected online.

References
1.
Strosberg  JR, Al-Toubah  T, Cives  M.  Evaluating risks and benefits of evolving systemic treatments of neuroendocrine tumors  [published online February 14, 2019].  JAMA Oncol. doi:10.1001/jamaoncol.2018.6694PubMedGoogle Scholar
2.
Kaderli  RM, Spanjol  M, Kollár  A,  et al.  Therapeutic options for neuroendocrine tumors: a systematic review and network meta-analysis  [published online February 14, 2019].  JAMA Oncol. doi:10.1001/jamaoncol.2018.6720PubMedGoogle Scholar
×